The immuno-oncology market has grown at a compound rate of 10%, from $57 billion to $69 billion in 2021. It is expected to reach around $98 billion by 2025.

This is a highly competitive market, so companies in this sector have to innovate rapidly by creating novel drugs and therapies.

‍

Here are the top 30 innovative immuno-oncology companies in the US:

‍

Dragonfly Therapeutics 

CEO & Co-Founder - William Haney

Located in Massachusetts, Dragon Therapeutics is developing cancer treatments that promote immune responses against cancer are being developed. The company's platform is developing revolutionary first-in-class therapies targeted at natural killer cells and other innate immune system cells.
‍

Zymeworks

CEO - Kenneth Galbraith

Located in British Columbia, Zymeworks is dedicated to the development, commercialization, and discovery of next-generation multifunctional biotherapeutics. Zanidatamab, the company's flagship clinical candidate, is a novel Azymetric HER2-targeted bispecific antibody that is now being tested in several Phase 1, Phase 2, and pivotal clinical trials around the world as a targeted therapeutic option for patients with HER2-positive solid tumors. 

Verastem Oncology

CEO - Brian Stuglik

Located in Massachusetts, Verastem Oncology is developing novel treatments for cancer patients. COPIKTRA (duvelisib), the company's first commercial product, is for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after two or more prior therapies, as well as relapsed or refractory follicular lymphoma after two or more prior systemic therapies. 

Gritstone bio

CEO & President & Co-Founder - Andrew Allen

Located in California, Gritstone bio is developing tailored cancer immunotherapies to combat a variety of cancers and infectious disorders. 

‍

Pieris Pharmaceuticals

CEO & President - Stephen Yoder

Located in Massachusetts, Pieris Pharmaceuticals is focused on discovering and developing biotherapeutics in the Anticalin class. 

Anticalin proteins are modified forms of lipocalins, which are human proteins that bind, store, and transport a wide range of chemicals naturally. 

Alaunos Therapeutics

CMO - Francois Lebel

Located in Texas, Alaunos Therapeutics Alaunos is focused on adoptive TCR-T cell therapy for the treatment of solid malignancies. It attacks cancer at its source by developing cell treatments that target Neoantigens (neoAg), which are produced as a result of genomic alterations.

Genocea

CTO - Raymond Stapleton, Jr.

Located in Massachusetts, Genocea focuses on creating innovative vaccines and immunotherapies to treat diseases with high unmet medical needs. Using  it's ATLAS™ technology can profile each patient's T cell responses to possible tumor targets, or antigens, in great detail. ATLAS targets antigens that trigger anti-tumor T cell responses as well as inhibitory antigens, known as Inhibigens™, that induce pro-tumor immune responses.

ImmunityBio

CEO - Richard Adcock

Located in California, ImmunityBio is developing next-generation treatments that stimulate immunogenic pathways in cancer and infectious disease patients. To develop long-term immunological memory, the company's immunotherapy platform engages both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems.

Galectin Therapeutics

CEO & President - Joel Lewis

Located in Georgia, Galectin Therapeutics focuses on drug development to find novel treatments for fibrotic illness, cancer, and a few other ailments. 

Syndax 

CEO - Michael A. Metzger

Located in Massachusetts, Syndax is working on a pipeline of combination medicines for a variety of cancers. Entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, are two of the company's product prospects. 

Allogene Therapeutics

CEO & President - David Chang

Located in California, Allogene Therapeutics is a clinical-stage biotechnology company specializing in developing allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer treatment. The company's pipeline includes several allogeneic CAR T therapies and UCART19 which is intended for the treatment of acute lymphoblastic leukemia (ALL).

Asher Biotherapeutics 

CEO - Craig Gibbs

Located in California, Asher Biotherapeutics develops targeted immunotherapies to treat cancer and other diseases. Their cis-targeting platform enables the activation of immune cell types to take on cancer cells with minimum side effects. 

Rubius Therapeutics

CEO - Pablo Cagnoni

Located in Massachusetts, Rubius Therapeutics is a pioneer in developing Red Cell Therapeutics™ (RCTs) using their proprietary RED PLATFORM™. The RCTs are potent, selective, and ready-to-use cellular therapies that can be used to treat autoimmune diseases and cancer.

Marengo Therapeutics

CEO - Zhen Su

Located in Massachusetts, Marengo Therapeutics is a pioneer in developing therapies that boost the body's immune system to fight cancer. Using their proprietary therapeutic platform, the company boosts the patient's T cells to amplify their anti-tumor activity while promoting long-lasting immunity.

Catamaran Bio

CEO & President - Alvin Shih

Located in Massachusetts, Catamaran Bio develops off-the-shelf, allogeneic immune cell therapies that are safe and effective using their proprietary TAILWIND™ platform to treat cancer and immune disorders. 

Obsidian Therapeutics

CEO - Paul Wotton

Located in Massachusetts, Obsidian Therapeutics is developing next-generation controlled cell and gene therapies are being developed to bring adoptive immunotherapy to every cancer patient. 

Odyssey Therapeutics

CEO & Founder - Gary D. Glick

Located in Massachusetts, Odyssey Therapeutics aims to create next-generation precision medicine for patients with cancer and inflammatory diseases. The Odyssey team can quickly identify relevant targets and optimize therapeutic assets for clinical development using their in-house intellectual capital.

‍

Apexigen

CEO & President - Xiaodong Yang

Located in California, Apexigen is a clinical-stage biopharmaceutical company that uses its proprietary antibody-drug discovery platform to develop drugs that enhance tumor-specific immunity.

‍

Artiva Biotherapeutics

CEO & President - Fred Aslan

Located in California, Artiva develops off-the-shelf therapies like allogeneic NK cell therapies, including CAR-NK cell therapies designed to treat solid tumors or hematologic malignancies. Its mission is to deliver safe and easily accessible cancer therapies to patients.

Fate Therapeutics

CEO & President - Scott Wolchko

Located in California, Fate Therapeutics is a clinical-stage biopharmaceutical company developing cellular immunotherapies for cancer and immune disorders. Their therapy pipeline includes natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to work in conjunction with current cancer therapies such as immune checkpoint inhibitors and monoclonal antibodies. 

ALX Oncology

CEO & President - Jaume Pons

Located in California, ALX Oncology is developing a pipeline of pharmaceutical candidates based on expertise in protein engineering and oncology, led by the CD47 blocker evorpacept, which is currently in phase 1 and 2 clinical trials. To avoid detection by the immune system, cancer cells use CD47, a cell surface protein, as a don't eat me signal. 

Filtricine

CEO - John Chant

Located in California, Filtricine has developed targeted nutrient deprivation (TND) therapy, which focuses on taking away nutrients critical for the growth of cancer cells. This helps to exploit metabolic dependencies to stop cancer from spreading.

OncoMyx Therapeutics

CSO - Leslie Sharp

Located in Arizona, OncoMyx Therapeutics develops immunotherapies that create an immune response to fight cancer. Its proprietary myxoma platform targets hematologic and solid tumors with a unique oncolytic virus called myxoma and a novel patented systemic delivery approach.

ArsenalBio

CEO & Co-Founder - Ken Drazan

Located in California, ArsenalBio is a programmable cell therapy company that uses CRISPR-enabled genome editing to engineer living medicines that attack cancer and improve patient lives.

Pyxis Oncology

CEO & President - Lara S. Sullivan

Located in Massachusetts, Pyxis Oncology develops biologics that overcome suppression and target tumor cells. They believe that antibody-drug candidates (ADCs) and immunotherapies hold the potential to improve patient lives and target difficult-to-treat cancers. 

Arch Oncology

CEO & President - Laurence Blumberg

Located in California, Arch Oncology is a clinical-stage company that develops antibody therapies to treat hematologic malignancies and solid tumors. Their lead candidate AO-176 is used to treat patients with solid tumors and is currently going through Phase 1/2 clinical trials. AO-176 can directly kill tumor cells and induce DAMPs (Damage Associated Molecular Patterns), resulting in Immunogenic Cell Death.

Rakuten Medical

CSO - Miguel Garcia-Guzman

Located in California, Rakuten Medical is developing cell-targeting investigational therapies on its Illuminox™ technology platform. These therapies are known to demonstrate selective cell killing and tumor necrosis in preclinical studies. 

Triumvira Immunologics

CEO & President - Paul Lammers

Located in Texas, Triumvira Immunologics is developing a novel and proprietary T cell Antigen Coupler (TAC) technology that is thought to be safer and more effective than some of the current cancer treatments like antigen receptor (CAR) and engineered T cell receptor (TCR) therapies.

Inimmune

CEO & President - Evans Jay

Located in Montana, Inimmune is developing next-generation immunotherapies for the treatment of autoimmunity and cancer.

Arcus Biosciences

CEO - Terry Rosen

Located in California, Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing therapies for cancer using the ATP-adenosine pathway, a crucial pathway associated with immunosuppression in a tumor microenvironment. The company's product pipeline includes Etrumadenant, AB680, and Domvanalimab.

‍

Scispot is on a mission to empower bioentrepreneurs and make workflow automation possible for every life science lab on this planet. To learn more about Scispot and its no-code digital toolkit for lab digitalization and automation, book a demo here.